RxDoctor Payments Data

Muneer Assi, DO

Internal Medicine · El Paso, TXNPI 1598721904

Payments from drug & device makers

$7,071in general payments, 2019–2025

Across 375 payments — averaging $18.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$725
  • AbbVie$690
  • Amarin Pharma, Inc.$655
  • Novo Nordisk$514
  • Johnson & Johnson$494
  • Pfizer$473
  • plus $4K from 35 others

What the payments were for

  • Food & beverage$7,045100%
  • Education$260%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,071 in reported general payments places this provider in the 90th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$284,555
Medicare patients
841
Services billed
4,102

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide154$169,809
EliquisApixaban77$93,971
OzempicSemaglutide53$70,493
JanuviaSitagliptin Phosphate56$67,706
XareltoRivaroxaban49$59,484
MyrbetriqMirabegron47$53,343
TrulicityDulaglutide28$32,750
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog28$27,378
VascepaIcosapent Ethyl22$23,285
JardianceEmpagliflozin21$19,410
FarxigaDapagliflozin Propanediol15$18,926
Repatha SureclickEvolocumab13$12,363
JanumetSitagliptin Phos/Metformin Hcl11$10,172
Tresiba Flextouch U-200Insulin Degludec14$9,566
Dexlansoprazole DrDexlansoprazole16$6,887

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$725$202,560182 claims
PfizerEliquis$473$93,97177 claims
MerckJanuvia, Janumet$104$77,87767 claims
Novo NordiskOzempic$514$70,49353 claims
Johnson & JohnsonXarelto$494$59,48449 claims
Astellas Pharma US IncMyrbetriq$266$53,34347 claims
AstraZenecaFarxiga, Symbicort$153$24,47629 claims
Boehringer IngelheimJardiance$221$19,41021 claims
AbbVieSynthroid$690$4,28071 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in El Paso

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →